LKFT Company Profile and Key Details

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Lakefront Biotherapeutics N.V. (NASDAQ:LKFT) closed at $30.36 USD, losing -$0.36 (-1.17%) from the previous close of $30.72. The stock is currently mid-range between its 52-week high and low $25.68 and $37.78. With a market capitalization of about $2.00 billion, Lakefront Biotherapeutics N.V. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.12). Key stats such as the average daily volume over the past year has been around 242.86 thousand shares, trading with heavier-than-usual volume. Headquartered in Mechelen, None, Lakefront Biotherapeutics N.V. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Henry O. Gosebruch, the company employs approximately 452 people and listed since May 05, 2005. Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation.

Lakefront Biotherapeutics N.V. has 65.48 million shares outstanding. The public float is 818.81 million shares, elevated short interest at 5.80% of float. This equals 2.32 million shares. The short ratio is 14.72 days. Institutional investors hold 30.27% of the float. Insiders own 25.35%.

Lakefront Biotherapeutics N.V. trades at a P/E ratio of 2.94, slightly below the S&P 500 average, with a price-to-sales ratio of 1.77 and a price-to-book ratio of 0.6 suggesting the stock is closer to book value. The P/FCF stands at -8.88, also below market averages.

Valuation shows Lakefront Biotherapeutics N.V. trading at a premium to the broader market with a P/E of 2.94. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $45.00, suggesting 48.22% upside. Our AI forecast model points to short-term strength (6.19% over two weeks), a medium-term rise (103.43% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Lakefront Biotherapeutics N.V. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.19%, with price expected at $32.24 by October 07, 2026, within a range of $31.27 to $33.27 3-Month Outlook: Projected rise of 103.43%, reaching $61.76 by December 22, 2026, with a range of $61.62 to $61.89. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by September 23, 2027, within a range of $0.00 to $0.00.